OncoZenge AB — Investor Relations & Filings

OncoZenge AB is a clinical-stage pharmaceutical company developing innovative treatments for oral pain. The company's lead product candidate, BupiZenge™, is a lozenge formulation based on the well-established local anesthetic bupivacaine. It is designed to provide targeted, local pain relief for the primary indication of oral mucositis, a severe and painful side effect of cancer treatments such as chemotherapy and radiotherapy. BupiZenge™ aims to address a significant unmet medical need for a safe, effective, and non-opioid treatment to improve patients' quality of life. Having completed Phase 2 trials, the product is advancing towards a pivotal Phase 3 study following regulatory guidance from the EMA and FDA. The technology also has potential applications in other oral pain conditions.